DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most...

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...

INDICATION: Sepsis; liver disease Patient sample and mouse studies suggest inhibiting NMI could help treat sepsis and liver injury, and inhibiting IFI35 could help treat sepsis. In serum samples from sepsis patients, NMI levels were...

While one of the biggest problems in infectious diseases is the overuse of antibiotics, few point-of-care tools are available to help physicians decide when and what to prescribe. Focusing on host genes rather than microbial...

While a new protocol for validating antibodies from the Structural Genomics Consortium goes part way toward addressing one of the biggest sources of irreproducibility in academic research, stakeholders agree a widespread solution will likely require...

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...

Imprimis also said it discontinued a Phase III program for Impracor, a topical cream formulation of 10% ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), that uses Accudel technology. In August, Imprimis said it would delay the...

Sufficiently graft-ifying Opsona Therapeutics Ltd. took the rare step of turning down money in last week's series C round, as the immunology company capped the financing at €33 million ($43 million) to avoid dilution. The...